生物制剂与小分子药物治疗溃疡性结肠炎的疗效比较:系统评价与网络Meta分析
该网络Meta分析纳入36项3期随机对照试验共14270例中重度溃疡性结肠炎患者,比较生物制剂与小分子药物诱导和维持缓解的疗效。乌帕替尼在诱导临床缓解、内镜改善及维持内镜改善方面排名最高,瑞莎珠单抗和古塞奇尤单抗在组织学缓解方面排名靠前。
要点
- 乌帕替尼在诱导临床缓解(99.6%)和内镜改善(99.2%)方面排名最高。
- 瑞莎珠单抗在诱导组织学缓解方面排名第一(89.4%)。
- 乌帕替尼在维持组织学缓解方面排名第一(93.1%)。
核心结论
- 乌帕替尼在实现临床缓解、内镜改善和缓解以及组织学缓解方面似乎优于其他疗法。
- 瑞莎珠单抗和古塞奇尤单抗等新型生物制剂在实现这些结局方面排名靠前。
- 本研究强调小分子药物和新型选择性白细胞介素-23抑制剂可作为其他生物制剂的替代选择。
研究设计与样本
- 系统评价与网络Meta分析,检索截至2024年5月的文献。
- 纳入3期安慰剂或阳性对照随机对照试验,共36项研究、14270例溃疡性结肠炎患者。
- 主要结局为诱导和维持内镜改善(Mayo内镜评分[MES]≤1)。
- 次要结局为诱导和维持临床缓解、内镜缓解(MES=0)和组织学缓解。
- 基于随机对照试验设计和既往生物制剂暴露进行亚组分析。
主要发现
- 乌帕替尼在诱导临床缓解(99.6%)和内镜改善(99.2%)方面排名最高,瑞莎珠单抗分别以91.4%和82.3%紧随其后。
- 维持内镜改善方面,乌帕替尼排名第一(98.6%),菲戈替尼200 mg排名第二(79.2%)。
- 诱导组织学缓解方面,瑞莎珠单抗排名第一(89.4%),古塞奇尤单抗排名第二(88.3%)。
- 维持组织学缓解方面,乌帕替尼排名第一(93.1%),古塞奇尤单抗排名第二(89.5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Treatment options for moderate to severe ulcerative colitis (UC) are increasing rapidly, but the lack of comparative efficacy trials makes treatment choices a clinical challenge. This network-meta-analysis aimed to compare the relative efficacy of biologics and small molecules in achieving remission in patients with moderate to severe UC. METHODS: The literature was searched up to May 2024. Phase 3 placebo or active comparator randomized controlled trials were included. The primary outcome was induction and maintenance of endoscopic improvement (Mayo Endoscopic Score [MES] ≤1). Secondary outcomes were the induction and maintenance of clinical remission, endoscopic (MES = 0) and histological remission. A sub-analysis was performed based on the randomized controlled trial design and previous exposure to biologic therapy. RESULTS: We identified 36 studies that met our inclusion criteria, with 14,270 patients with UC. Upadacitinib ranked highest in inducing clinical remission (99.6%), and endoscopic improvement (99.2%), followed by risankizumab (91.4%) and (82.3%), respectively. In maintenance of endoscopic improvement, upadacitinib ranked first (98.6%) followed by filgotinib 200 mg (79.2%). Risankizumab ranked first in the induction of histological remission (89.4%), followed by guselkumab (88.3%). Upadacitinib ranked first (93.1%) in maintaining histological remission, followed by guselkumab (89.5%). CONCLUSION: Upadacitinib appears to be superior to other therapies in achieving clinical remission, endoscopic improvement and remission, and histological remission. Furthermore, novel biologics such as risankizumab and guselkumab ranked high in achieving these outcomes. This study highlights the efficacy of small molecule drugs and novel selective interleukin-23s as alternatives to other biologics.
引用
- Shehab M, Alrashed F, Alsayegh A, et al. Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol. 2024. PMID: 39182898. doi:10.1016/j.cgh.2024.07.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。